Amid a deteriorating macroeconomic backdrop, orthopedic industry stocks have shown resiliency relative to the broader public markets. This enables management teams to breathe a sigh of relief, driven in part by expectations for a long-awaited pickup in procedure volumes, as they and investors have watched valuations tumble over recent years due to COVID-19 headwinds, supply-chain backlogs, and other industry forces.
Published in MedTech Strategist
Authors: Oded Ben-Joseph, PhD, Thomas F. Busby, and
Derrick Holmes, CFA
Abstract:
Amid a deteriorating macroeconomic backdrop, orthopedic industry stocks have shown resiliency relative to the broader public markets. This enables management teams to breathe a sigh of relief, driven in part by expectations for a long-awaited pickup in procedure volumes, as they and investors have watched valuations tumble over recent years due to COVID-19 headwinds, supply-chain backlogs, and other industry forces.
Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON–(BUSINESS WIRE)-July 8, 2025-Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients […]
Read MoreOutcome Capital Life Science Market Pulse June 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?